BILASTINE: A DRUG REVIEW
Author(s):
Jitendra kumar, SHIVAM BABRA, DEEPAK SAINI, ANSHU TIWARI
Keywords:
Allergic rhinitis, antihistamines, bilastine, urticaria
Abstract
An effective and highly specific H1-antihistamine, bilastine is licenced to treat allergic urticaria and rhinoconjunctivitis. The information that is currently known on the use of bilastine in the treatment of allergic diseases in various age groups, including school-age children and adolescents, younger and older people, is included in this page. Adults and adolescents over the age of 12 get oral bilastine at a dose of 20 mg once day, while children between the ages of 6 and 12 receive oral bilastine at a dose of 10 mg once daily. Clinical studies have shown that it is effective at reducing wheals and itching in urticaria patients as well as nasal and ocular symptoms in people with allergic rhinitis. It acts quickly and effectively for a long time. Bilastine's potential for drug-drug interactions is constrained because it does not undergo considerable metabolism and does not interact with the CYP450 system. In individuals with renal or hepatic impairment, as well as in the elderly, there are no dose changes necessary. Bilastine is often well tolerated, even when given in dosages that are beyond the recommended amount. It has very little sedative effects and neither anticholinergic nor cardiotoxic effects, nor does it penetrate the central nervous system. It has been demonstrated to enhance life quality as it relates to health. From school-age children to senior patients, bilastine is an useful alternative for the treatment of individuals with allergic rhinoconjunctivitis or urticaria.
Article Details
Unique Paper ID: 157524

Publication Volume & Issue: Volume 9, Issue 7

Page(s): 469 - 473
Article Preview & Download


Share This Article

Join our RMS

Conference Alert

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024

Last Date: 15th March 2024

Call For Paper

Volume 10 Issue 10

Last Date for paper submitting for March Issue is 25 June 2024

About Us

IJIRT.org enables door in research by providing high quality research articles in open access market.

Send us any query related to your research on editor@ijirt.org

Social Media

Google Verified Reviews